Concentrations of tenofovir, lamivudine and efavirenz in mothers and children enrolled under the Option B-Plus approach in Malawi

Journal of Antimicrobial Chemotherapy

Volumn 71, Issue 4, 2016, Pages 1027-1030

  Palombi, Leonardo ^a   Pirillo, Maria F ^b   Marchei, Emilia ^b   Jere, Haswell ^c   Sagno, Jean Baptiste ^c   Luhanga, Richard ^c   Floridia, Marco ^b   Andreotti, Mauro ^b   Galluzzo, Clementina Maria ^b   Pichini, Simona ^b   Mwenda, Ruben ^d   Mancinelli, Sandro ^a   Marazzi, Maria Cristina ^e   Vella, Stefano ^b   Liotta, Giuseppe ^a   Giuliano, Marina ^b  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

^b ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^c DREAM Program   (Malawi)

^d MINISTRY OF HEALTH   (Malawi)

^e LUMSA UNIVERSITY   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

EFAVIRENZ; LAMIVUDINE; TENOFOVIR; VIRUS RNA; BENZOXAZINE DERIVATIVE;

ADULT; ARTICLE; BREAST FEEDING; BREAST MILK; DRUG BLOOD LEVEL; DRUG MILK LEVEL; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFANT; LIMIT OF QUANTITATION; LIQUID CHROMATOGRAPHY; MAJOR CLINICAL STUDY; MALAWI; MALE; MATERNAL PLASMA; NONHUMAN; PREGNANCY; PUERPERIUM; TANDEM MASS SPECTROMETRY; TREATMENT RESPONSE; VERTICAL TRANSMISSION; VIRUS LOAD; VIRUS RESISTANCE; CD4 LYMPHOCYTE COUNT; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV INFECTIONS; PREGNANCY COMPLICATION; PREVENTION AND CONTROL; TRANSMISSION; YOUNG ADULT;

ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BENZOXAZINES; CD4 LYMPHOCYTE COUNT; CHROMATOGRAPHY, LIQUID; FEMALE; HIV INFECTIONS; HUMANS; INFANT; INFECTIOUS DISEASE TRANSMISSION, VERTICAL; LAMIVUDINE; MALAWI; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; TANDEM MASS SPECTROMETRY; TENOFOVIR; VIRAL LOAD; YOUNG ADULT;

EID: 84964374712     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkv435     Document Type: Article

References (20)

1. WHO. Consolidated Guidelines on the Use of Antiretroviral Drugs for Treating and Preventing HIV Infection: Recommendations for a Public Health Approach. 2013. http://www.who.int/hiv/pub/guidelines/arv2013/download/en/index.html.
2. CDC. Impact of an innovative approach to prevent mother-to-child transmission of HIV-Malawi, July 2011-September 2012. MMWR Morb Mortal Wkly Rep 2013; 62: 148-51.
3. Marchei E, Escuder D, Pallas CR et al. Simultaneous analysis of frequently used licit and illicit psychoactive drugs in breast milk by liquid chromatography tandem mass spectrometry. J Pharm Biomed Anal 2011; 55: 309-16.
4. Benaboud S, Pruvost A, Coffie PA et al. Concentrations of tenofovir and emtricitabine in breast milk of HIV-infected women in Abidjan, Cô te d'Ivoire, in the ANRS 12109 TEmAA Study, Step 2. Antimicrob Agents Chemother 2011; 55: 1315-7.
5. Mirochnick M, Taha T, Kreitchmann R et al. Pharmacokinetics and safety of tenofovir in HIV-infected women during labor and their infants during the first week of life. J Acquir Immune Defic Syndr 2014; 65: 33-41.
6. Shapiro RL, Holland DT, Capparelli E et al. Antiretroviral concentrations in breastfeeding infants of women in Botswana receiving antiretroviral treatment. J Infect Dis 2005; 192: 720-7.
7. Corbett AH, Kayira D, White NR et al. Antiretroviral pharmacokinetics in mothers and breastfeeding infants from 6 to 24 weeks post-partum: results of the BAN study. Antivir Ther 2014; 19: 587-95.
8. Mirochnick M, Thomas T, Capparelli E et al. Antiretroviral concentrations in breastfeeding infants of mothers receiving highly active antiretroviral therapy. Antimicrob Agents Chemother 2009; 53: 1170-6.
9. Palombi L, Pirillo MF, Andreotti M et al. Antiretroviral prophylaxis for breastfeeding transmission in Malawi: drug concentrations, virological efficacy and safety. Antivir Ther 2012; 17: 1511-9.
10. Schneider S, Peltier A, Gras A et al. Efavirenz in human breast milk, mothers', and newborns' plasma. J Acquir Immune Defic Syndr 2008; 48: 450-4.
11. Gandhi M, Mwesigwa J, Aweeka F et al. Hair and plasma data showthat lopinavir, ritonavir and efavirenz all transfer from mother to infant in utero, but only efavirenz transfers via breastfeeding. J Acquir Immune Defic Syndr 2013; 63: 578-84.
12. Olagunju A, Bolaji OO, Amara A et al. Development, validation and clinical application of a novel method for the quantification of efavirenz in dried breast milk spots using LC-MS/MS. J Antimicrob Chemother 2015; 70: 555-61.
13. Olagunju A, Bolaji O, Amara A et al. Breast milk pharmacokinetics of efavirenz and breastfed infants' exposure in genetically defined subgroups of mother-infant pairs: an observational study. Clin Infect Dis 2015; 61: 453-63.
14. Skhosana L, Steegen K, Bronze M et al. High prevalence of the K65R mutations in HIV-1 subtype C infected patients failing tenofovir-based first-line regimens in South Africa. PLoS One 2015; 19: e0118145.
15. Sunpath H, Wu B, Gordon M et al. High rate of K65R for antiretroviral therapy-naïve patients with subtype C HIV infections failing a tenofovircontaining first-line regimen. AIDS 2012; 26: 1679-84.
16. Van Zyl GU, Liu TF, Claassen M et al. Trend in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first and second-line antiretroviral treatment regimens. PLoS One 2013; 8: e67188.
17. Hoffmann CJ, Ledwaba J, Li JF et al. Resistance to tenofovir-based regimens during treatment failure of subtype C HIV-1 in South Africa. Antivir Ther 2013; 18: 915-20.
18. Aurpibul L, Puthanakit T. Review of tenofovir use in HIV-infected children. Pediatr Infect Dis J 2015; 34: 383-91.
19. Tremoulet AH, Capparelli EV, Patel P et al. Population pharmacokinetics of lamivudine in human immunodeficiency virus-exposed and-infected infants. Antimicrob Agents Chemother 2007; 51: 4297-302.
20. Viljoen M, Gous H, Kruger HS et al. Efavirenz plasma concentrations at 1, 3 and 6 months post-antiretroviral therapy initiation in HIV type 1-infected South African children. AIDS Res Hum Retrovir 2010; 26: 613-9.